Tonix Pharmaceuticals Holding Stock Buy Hold or Sell Recommendation
TNXP Stock | USD 0.16 0.01 6.67% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Tonix Pharmaceuticals Holding is 'Strong Sell'. Macroaxis provides Tonix Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding TNXP positions. The advice algorithm takes into account all of Tonix Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Tonix Pharmaceuticals' buy or sell advice are summarized below:
Real Value 2.29 | Target Price 8.67 | Hype Value 0.15 | Market Value 0.16 | Naive Value 0.21 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Tonix Pharmaceuticals Holding given historical horizon and risk tolerance towards Tonix Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for Tonix Pharmaceuticals Holding, the advice is generated through an automated system that utilizes algorithms and statistical models.
Tonix |
Execute Tonix Pharmaceuticals Buy or Sell Advice
The Tonix recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Tonix Pharmaceuticals Holding. Macroaxis does not own or have any residual interests in Tonix Pharmaceuticals Holding or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Tonix Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Excited | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Tonix Pharmaceuticals Trading Alerts and Improvement Suggestions
Tonix Pharmaceuticals generated a negative expected return over the last 90 days | |
Tonix Pharmaceuticals has high historical volatility and very poor performance | |
Tonix Pharmaceuticals has some characteristics of a very speculative penny stock | |
Tonix Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
The company reported the previous year's revenue of 7.77 M. Net Loss for the year was (116.66 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Tonix Pharmaceuticals Holding currently holds about 145.48 M in cash with (102 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.38, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Tonix Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
Latest headline from MacroaxisInsider: Acquisition by Bradley Saenger of 282000 shares of Tonix Pharmaceuticals at 0.368 subject to Rule 16b-3 |
Tonix Pharmaceuticals Returns Distribution Density
The distribution of Tonix Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Tonix Pharmaceuticals' future price movements. The chart of the probability distribution of Tonix Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Tonix Pharmaceuticals Holding price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Tonix Pharmaceuticals returns is essential to provide solid investment advice for Tonix Pharmaceuticals.
Mean Return | -0.53 | Value At Risk | -8.57 | Potential Upside | 10.71 | Standard Deviation | 7.31 |
Return Density |
Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Tonix Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Tonix Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Tonix Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tonix Pharmaceuticals Holding backward and forwards among themselves. Tonix Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Tonix Pharmaceuticals' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Millennium Management Llc | 2023-12-31 | 27 K | Commonwealth Equity Services Inc | 2023-12-31 | 20.1 K | Northern Trust Corp | 2023-12-31 | 16.3 K | Barry Investment Advisors, Llc | 2024-03-31 | 13.3 K | First Western Trust Bank | 2023-12-31 | 10.3 K | Crew Capital Management, Ltd. | 2023-12-31 | 10 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 8 K | Advisor Group Holdings, Inc. | 2023-12-31 | 657 | Royal Bank Of Canada | 2023-12-31 | 297 | Armistice Capital, Llc | 2023-12-31 | 3.8 M | Sabby Management Llc | 2023-12-31 | 3.1 M |
Tonix Pharmaceuticals Cash Flow Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | (13.8M) | 66.0M | 101.6M | (58.4M) | (95.3M) | (90.5M) | |
Free Cash Flow | (26.7M) | (57.1M) | (110.9M) | (146.2M) | (109.9M) | (104.4M) | |
Capital Expenditures | 17K | 8.6M | 35.3M | 48.1M | 7.9M | 6.9M | |
Net Income | (28.6M) | (50.5M) | (92.3M) | (110.2M) | (116.7M) | (110.8M) | |
End Period Cash Flow | 11.3M | 77.3M | 178.9M | 120.5M | 24.9M | 37.8M | |
Depreciation | 26K | 27K | 50K | 1.3M | 4.3M | 4.5M | |
Other Non Cash Items | 15.0M | 1.4M | 3M | 14.5M | (2.3M) | (2.2M) | |
Dividends Paid | 3.3M | 2.5M | 451K | 6.7M | 7.7M | 8.0M | |
Change To Netincome | 1.5M | 4.2M | 10.9M | 10.9M | 12.6M | 13.2M | |
Investments | (17K) | (8.6M) | (35.3M) | (48.1M) | (33.3M) | (31.6M) |
Tonix Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Tonix Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Tonix Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Tonix stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.7 | |
β | Beta against NYSE Composite | 1.96 | |
σ | Overall volatility | 7.31 | |
Ir | Information ratio | -0.09 |
Tonix Pharmaceuticals Volatility Alert
Tonix Pharmaceuticals Holding is displaying above-average volatility over the selected time horizon. Tonix Pharmaceuticals Holding is a potential penny stock. Although Tonix Pharmaceuticals may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Tonix Pharmaceuticals Holding. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Tonix instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Tonix Pharmaceuticals Fundamentals Vs Peers
Comparing Tonix Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Tonix Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Tonix Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Tonix Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Tonix Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Tonix Pharmaceuticals by comparing valuation metrics with those of similar companies.
Better Than Average | Worse Than Average | Compare Tonix Pharmaceuticals to competition |
Fundamentals | Tonix Pharmaceuticals | Peer Average |
Return On Equity | -0.75 | -0.31 |
Return On Asset | -0.39 | -0.14 |
Operating Margin | (7.23) % | (5.51) % |
Current Valuation | (1.89 M) | 16.62 B |
Shares Outstanding | 95.54 M | 571.82 M |
Shares Owned By Institutions | 19.86 % | 39.21 % |
Number Of Shares Shorted | 1.25 M | 4.71 M |
Price To Earning | (0.69) X | 28.72 X |
Price To Book | 0.15 X | 9.51 X |
Price To Sales | 2.00 X | 11.42 X |
Revenue | 7.77 M | 9.43 B |
EBITDA | (114.09 M) | 3.9 B |
Net Income | (116.66 M) | 570.98 M |
Cash And Equivalents | 145.48 M | 2.7 B |
Cash Per Share | 3.38 X | 5.01 X |
Total Debt | 9.81 M | 5.32 B |
Debt To Equity | 0 % | 48.70 % |
Current Ratio | 12.05 X | 2.16 X |
Book Value Per Share | 1.80 X | 1.93 K |
Cash Flow From Operations | (102 M) | 971.22 M |
Short Ratio | 0.52 X | 4.00 X |
Earnings Per Share | (6.85) X | 3.12 X |
Target Price | 3.5 | |
Number Of Employees | 103 | 18.84 K |
Beta | 2.23 | -0.15 |
Market Capitalization | 14.98 M | 19.03 B |
Total Asset | 154.46 M | 29.47 B |
Retained Earnings | (600.66 M) | 9.33 B |
Working Capital | 28.88 M | 1.48 B |
Current Asset | 46.36 M | 9.34 B |
Current Liabilities | 6.65 M | 7.9 B |
Net Asset | 154.46 M |
Note: Acquisition by Bradley Saenger of 282000 shares of Tonix Pharmaceuticals at 0.368 subject to Rule 16b-3 [view details]
Tonix Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Tonix . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Tonix Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Tonix Pharmaceuticals Holding? Buying financial instruments such as Tonix Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 5.1M | 6.4M | 9.5M | 10.0M | Total Assets | 240.9M | 225.7M | 154.5M | 162.2M |
Use Investing Ideas to Build Portfolios
In addition to having Tonix Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Rentals Thematic Idea Now
Rentals
Companies providing rental and leasing services to public and business. The Rentals theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Rentals Theme or any other thematic opportunities.
View All Next | Launch |
Check out Tonix Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Tonix Stock analysis
When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is Tonix Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tonix Pharmaceuticals. If investors know Tonix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tonix Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.85) | Revenue Per Share 0.456 | Return On Assets (0.39) | Return On Equity (0.75) |
The market value of Tonix Pharmaceuticals is measured differently than its book value, which is the value of Tonix that is recorded on the company's balance sheet. Investors also form their own opinion of Tonix Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Tonix Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tonix Pharmaceuticals' market value can be influenced by many factors that don't directly affect Tonix Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tonix Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tonix Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tonix Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.